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Abstract 
Patient-reported outcomes and surveying has increased in clinical settings in order to assess 
outcomes and patient health status. However, there is a lack of these assessments from a pediatric 
standpoint, an inpatient standpoint, and family perspective. In addition to health status and 
overall clinic experience, expanding the self-reported evaluation to include quality of life on 
physical and psychosocial levels will provide a more comprehensive evaluation of the patients’ 
health services. The PedsQL ™ scale scores four domains: physical, emotional, social, and 
school/work functioning. It includes a parent-proxy report as well as self-report for patients ages 
5 to 18 years. Infant scales are also available for children 1-24 months of age that include a 
parent-proxy report.  
 
The Wiskott-Aldrich Foundation aims to improve quality of life (QoL) surveying to best reflect 
patient and family sentiments for patients with the immunodeficiency disorder, Wiskott-Aldrich 
Syndrome (WAS). WAS is a genetically inherited immunodeficiency disease that severely 
suppresses the immune system to make the patient dangerously susceptible to autoimmune 
disorders and malignancies. The comparison of family impact and PedsQL™ can paint a picture 
of the family’s coping with WAS and what they may need beyond clinical treatment of WAS.   
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I. Introduction 
 
Wiskott-Aldrich Syndrome (WAS) is a genetically inherited immunodeficiency disease that 
occurs almost exclusively in males. Diagnosis of WAS is typically characterized by the triad of 
microthrombocytopenia, the decrease in the size and number of platelets, eczema, and severe 
infections. Platelets are the blood cells involved in clotting, so these patients have a reduced 
ability to form blood clots. This leads to symptoms such as easy bruising or episodes of 
prolonged bleeding after minor traumas. WAS largely affects white blood cells, which are 
responsible for immunity. Patients easily develop inflammatory disorders – especially severe 
eczema and skin irritations (Bosticardo et al., 2009). The large danger lies in the likelihood of 
patients developing autoimmune disorders because of their lack of immune system function and 
the body attacking its own tissues and organs. WAS is prematurely lethal and historically has an 
average survival of 20 years of age (Sullivan et al., 1994).  
 
A pediatric quality of life (QoL) assessment exists, called PedsQL™, to determine a summary 
score for physical health, psychosocial health, and overall QoL on a scale of 0 to 100. There are 
23 items that assess 4 areas: physical, emotional, social, and school/work. The patient scores 
each item on a 5-point scale from “never a problem” to “almost always a problem”. Each 
dimension is scored separately (Varni et al., 2006). A family impact module is also 
administered that includes Parent QoL, family function, and worry. The comparison of family 
impact and PedsQL™ can paint a picture of the family’s coping with WAS and what they may 
need beyond clinical treatment of WAS.   
 
II. Background 
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The defect responsible for Wiskott-Aldrich Syndrome was initially identified in 1994 
where the cytoplasmic WAS protein, or WASP, was compromised. WASP has various 
functions such as cytoskeletal organization, cell regulation, signal transduction, and 
immune synapse development (Ochs and Notarangelo, 2005). Therefore, disorder in the 
WASP affects the function of hematopoietic function and therefore damages lymphocyte 
and platelet counts in patients with the disorder. Genetic testing can show various 
mutations along the WAS gene. Those missing the WASP expression experience 
premature mortality. Some may have X-linked thrombocytopenia, or XLT, which is less 
severe. Another seen phenotype is X-linked neutropenia caused by a missense mutation at 
the Cdc42-binding site of the protein (Ochs and Thrasher, 2006).  
 
Improvements in supportive care and treatment regimens have been relatively recent. 
Studies conducted by the Primary Immune Deficiency Consortium (PIDTC) are exploring 
immunological and clinical effects of hematopoietic cell transplant (HCT) in patients for 
WAS compared to other treatment options. Analysis of pre-transplant immunity 
compared to post-transplant conditions will reveal the most effective treatment option to 
maximize not only years of life, but also quality of life of young patients.  
 
The prevention of infections must be addressed immediately after diagnosis. Intravenous Ig 
(IVIG) is typically used alongside more invasive treatments. Patients are typically put on 
prophylactic antibiotics or lifeline prophylactic penicillin for patients who have undergone 
splenectomy (Notarangelo, et al., 2008). It is currently recommended that all patients with WAS 
be considered for HSCT (hematopoietic stem cell transplantation) at a young age of less than 5 
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years old. Donor type is a very important consideration as graft versus host disease (GvHD) is a 
common adverse event. Post-transplant complications include mixed chimerism, autoimmunity, 
infections, malignancy such as lymphoproliferative disorder, B-cell lymphoma, large-cell 
lymphoma, myelodysplasia, and myeloid leukemia (Pai and Notarangelo, 2010). Full donor, 
successful engraftment limits the risk of these malignancies. Research is currently focused on 
gene therapy treatments, which avoid the graft rejection and GvHD barriers that HSCT have. The 
gene would be corrected using viruses to integrate the desired gene back into the genome. There 
are many efficacy and safety ‘gaps’ in the gene therapy treatment field, but the addition of these 
new advances could potentially be a new model for the care of various primary 
immunodeficiency disorders. 
 
Wiskott-Aldrich Syndrome Epidemiology 
 
WAS is a monogenic X-linked recessive disorder, meaning boys who inherit the abnormal gene 
are affected by the disease whereas girls who inherit the gene are typically healthy carriers of the 
disease. The gene responsible for the disorder is located on the short arm of the X-chromosome 
(Xp11.22-p11.23). The mutation in the WASp gene alters the function and expression of the 
protein that is involved in signaling, cytoskeletal arrangement, and actin polymerization. Two 
variations of diagnosis are X-linked thrombocytopenia (XLT) and X-linked neutropenia (XLN) 
(Ochs and Notarangelo, 2005). WAS diagnosis is scored based on severity on a scale of 0-5. 
WAS comprises of a group of serious, but rare disorders, affecting 1 in 250,000 live births and 
there are approximately 500 WAS patients in the U.S (Bosticardo et al., 2009).  The disease has 
a similar incidence in countries around the world. Patients with WAS are at a high risk for 
developing autoimmune complications and severe malignancies during the first decade of life. 
Diagnosis of WAS includes microthrombocytopenia, decreased IgM and increased IgA and IgE 
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levels, poor antibody response via infection or immunization, low CD8 levels, low NK cells, and 
severe allergies. Due to low immune function, patients have an overwhelming higher risk of 
developing severe infections due to herpes viruses (Herpes Simplex Virus 1 (HSV-1) and 
Varicella Zoster (VZV)) (Imai et al., 2004).   
 
 
Wiskott-Aldrich Syndrome Treatments 
 
Hematopoietic cell transplant (HCT) is currently the only remedying therapy for WAS 
patients. Because the mechanism of WAS is relatively newly understood, many short -
term outcomes have been published. The primary life-threatening complication following 
HCT is acute and/or chronic graft versus host disease, or GvHD. To prevent transplant 
rejection and prevent mixed chimerism, conditioning treatments similar to chemotherapy 
for cancer treatment is administered prior to HCT. The younger the patient, the more 
successful transplant is and fewer graft rejections are reported.  
 
Supportive therapies for patients diagnosed with WAS include antibiotic administration, 
immunoglobulin administration, minimizing allergy sources, and managing symptoms of 
mild immune cases such as eczema. If patient has bleeding episodes due to 
microthrombocytopenia, platelet transfusions may be administered. There are no 
therapies to treat severe malignancies such as lymphoma or other severe autoimmune 
conditions.   
 
Gene therapy (GT) is the newest treatment option to emerge for WAS. Boztug et al. in Germany 
were the first to treat patients using GT. The process involves the collection of peripheral blood 
CD34+ cells and transducing a WASP retrovirus vector. Patients would be administered a 
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conditioning regimen similar to that of HCT days prior to transduction. The study showed 57% 
and 69% expression of WASP-positive B-cells in patient 1 and 2, respectively. The higher 
expression meant better T cell and NK cell function and more production of antibodies that are 
important for immunization. Greater platelet counts to help with bleeding episodes were also 
accounted for (Boztug et al., 2010). Since this study, various centers around the world are 
implementing GT and are seeing successful reconstitution. The risk of GvHD and the potential 
risk in waiting for the proper donor for HCT would be eliminated with this method of treatment.  
 
Description of The Wiskott-Aldrich Foundation  
Mission: “The Wiskott-Aldrich Foundation is dedicated to serving children with Wiskott-Aldrich 
Syndrome and their families worldwide by funding research and providing educational, financial 
and emotional support.” 
 
The Wiskott-Aldrich Foundation was founded in 2003 to inform people of the disease, promote 
research, and provide support for WAS families. The WAF collaborates with families, 
physicians, researchers, patients, and charities to serve these families and link them to the 
resources they may need. In a time of vulnerability and uncertainty, families of children with 
WAS can turn to an organization whose mission is to improve the quality of life for WAS 
patients. The momentum created through this online resource and its presence in immune 
deficiency groups has fostered critical research to grow to better the lives of WAS patients 
worldwide. www.wiskott.org has over 90 pages of resources that is constantly being updated. On 
the portal, families can find the most current research, registries, financial resources, support 
groups, camps, and leading treatment institutions near them. Families are encouraged to share 
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their stories and engage in forums and attend events to not only become informed, but also to 
develop a community to help in coping with WAS.  
 
III. Scope of the Project 
 
The primary goal of the project was to improve the quality of life for patients and families of 
patients diagnosed with Wiskott-Aldrich syndrome through raising awareness of the effects of 
WAS and encouragement of questioning QoL through surveying. 
 
The personal objectives for the fieldwork experience were as follows: 
1. Research past QoL studies and effectiveness 
2. Familiarize self with PedsQL™ 
3. Understand scoring of QoL surveys 
4. Maintain IRB consents and QoL surveys through UCSF IRB 
5. Administer QoL surveys in various languages when needed 
6. Administer QoL surveys to UCSF WAS patients at cross-sectional visits 
7. Data entry of QoL results 
The Wiskott-Aldrich Foundation’s current research has the following objectives: 
1. Improve patient’s quality of life (QoL) 
2. Share the effects of WAS and treatment options on the QoL of patients with healthcare 
professionals and colleagues 
3. Encourage the administration of QoL surveys regularly 
4. Improve QoL surveying to best reflect patient and family sentiments 
5. Use QoL as a tool to help families and physicians assess treatment options 
6. Use QoL study results to impact other conditions outside of WAS on a global level 
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The Wiskott-Aldrich Foundation collaborates with research consortiums, such as the PIDTC, 
physicians, statisticians, patient advocacy groups, families, and volunteers to publish and share 
data on WAS and push for bettering the quality of life assessments to ultimately affect quality 
of care on a comprehensive level.  
 
IV. Public/Population Health Impact: Findings and Significance 
 
Although the results of the research cannot be disclosed in this paper due to confidentiality and 
grant renewal reasons, there has been extension research published on the effectiveness of 
quality of life surveying a pediatric healthcare setting to evaluate patient needs on a 
comprehensive level.  
 
Desai et al. assessed responsiveness, construct validity, and predictive validity of the PedsQL™ 
scale in an inpatient setting at Seattle Children’s Hospital using a prospective cohort of 7184 
participants from 1 month to 18 years of age. 4637 (64.5%) of the participants completed the 
survey when admitted, and 2694 (58.1%) of participants completed the follow-up survey after 
discharge weeks later. The study set out to evaluate response to clinical change in critically ill 
children to determine the effectiveness of quality improvement interventions. On the 0 to 100 
scale, the mean PedsQL™ scores were 22.1 for total, 29.4 for physical, and 17.1 for psychosocial 
(Desai et al., 2014). Improvement scores were derived by calculating the difference between 
scores on admission and those at follow-up. The study showed construct validity when testing 
patients with no chronic illness, who had much higher QoL scores compared to the chronically ill 
patients measured. The highest scores being physical QoL can be explained because patients in a 
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short-term inpatient setting have the focus of physical health improvement interventions. The 
score decreased by an average of 10-points with risks for prolonged length of stay (15% [95% 
CI, 13%-17%]), 30-day readmissions (8% [95% CI, 3%-14%]), and ED return visits (13% [95% 
CI, 6%-20%]) (Desai et al., 2014). The PedsQL™ model revealed strong responsiveness, 
construct validity and predictive validity for inpatient pediatric patients.  
 
In a paper by Panepinto et al., PedsQL™ scores were looked at for various diseases and 
comorbidities. Children without sickle cell disease and without other comorbidities had higher 
scores for most categories than children with sickle cell disease and medical/neurobehavioral 
comorbidities. Worry and communication sub scores were the only statistically significant low 
scores (Panepinto et.al, 2009). Figure 1 illustrates these results. 
Figure 1 
 
Nuss and Wilson examined health-related quality of life (HRQoL) of children who underwent a 
hematopoietic stem cell transplant (HSCT), which includes bone marrow, cord blood, or 
peripheral blood). Most WAS patients undergo this treatment to prolong life – both quantity and 
quality of life. The study found a lower quality of life reported in mothers, and a statistically 
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significant lower physical functioning score in mothers. Children and mothers felt more anxious 
with older age of transplant, while father felt less anxiety and worrying when child was 
transplanted at older age. Compared to healthy individuals, HSCT patients had increase fear of 
disease, anxiety, perfectionism, and sense of inadequacy. Mothers reported lower physical 
quality of life than fathers and children in multiple studies. It is hypothesized that mothers often 
assist more in the care of the transplanted children than fathers, and mothers may compare their 
child’s physical well-being to an ideal well-being that the child may not have. Increase in anxiety 
with increase in age may be due to the awareness factor. Older children may be more aware with 
higher procedural anxiety than younger children who do not remember or dwell on the 
procedure. It would be important to look at sibling QoL scores as well. Siblings of WAS patients 
are lucky in the genetic draw. Siblings are also with the transplanted children on a more regular 
basis, and may have more insight on physical and psychological quality of life.  
 
 
V. Conclusion 
Larger retrospective and prospect studies of children with WAS undergoing the various 
treatment options can uncover the best treatment, most successful conditioning regimen, 
and donor choice. Pre and post- treatment immunological data can provide insight into 
factors that affect survival and reconstitution. The continuation of quality of life s urvey 
administration also tells the story of patients and their families dealing with the disease. 
Healthcare professionals must be aware of these social aspects of illness to provide a 
comprehensive care plan.  
 
Quality of life scores in patients with WAS are significantly lower than those in healthy 
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patients. The Wiskott-Aldrich Foundation found that on average, patients and parents 
report similar QoL scores across all 4 domains, and that psychosocial QoL scores are 
significantly lower than physical QoL scores. We can also conclude that QoL in WAS is 
similar to QoL scores for other PIDs and chronic GvHD. When looking at treatment 
options, patients and families who had transplants reported higher QoL scores than 
those who did not. Because patients who are older at transplant report lower scores, it 
can be concluded that transplant at a younger age is beneficial on all domains. 
Ultimately, these results must be incorporated into psychosocial and emotional parts of 
care and treatment for all patients. Surveying must be administered at all annual visits 
to ensure patients and families are doing well emotionally and mentally apart from 
standard of care assessments. Support for siblings must be available, as they are 
affected with worry. After transplant, healthcare professionals should offer patient 
group support options and any emotional support possible to minimize worry in 
families. These groups are confronted with a rare condition that can be very isolating, 
and a community to understand their family function and perception of disease can 
ultimately improve quality of life and overall care of patient.   
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Appendices 
 
Competencies Addressed 
 
 
 
Fieldwork Reflection 
My work at UCSF Benioff Children’s Hospital involved the direct communication with patients 
and families with WAS. Patients that came in for diagnosis or follow-up treatment would have 
10-minutes set aside for me to consent them to a part of a PIDTC (Primary Immune Deficiency 
Competencies 
Addressed
Understanding 
family priorities 
and supporting 
families dealing 
with PID Understanding 
epidemiology of 
PID (Pediatric 
Immune 
Deficiencies)
Cultural 
perspectives on 
PID 
Infant, toddler, 
early childhood 
mental health
Working with 
family centered 
care in a 
healthcare 
environment
Determining 
family concerns, 
priorities, and 
needs
Ethics and 
professionalism
Conflict 
resolution in 
healthcare 
setting
Communication 
skills with 
vulnerable 
population
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Treatment Consortium) cross-sectional study where QoL surveys would be administered and 
evaluated. I had to get IRB approval and consent training which really opened my eyes to patient 
care settings – especially with vulnerable populations. I felt honored to be a part of such an 
inspiring team of healthcare professionals who dedicated their lives to immunology. The 
physicians I worked with on a daily basis were some of the leading researchers in the field, and 
have helped patients with WAS live close-to-normal lives with innovative therapies. I had the 
opportunity to sit in on meetings where they discussed every child who came into either inpatient 
or outpatient clinic, and evaluated every small part of their treatment down to their emotional 
experience to make sure the patient and their families were comfortable. I was so impressed that 
these brilliant minds knew every detail about every patient down to the kind of meals they 
wanted to have that day.  
The administration of the surveys was not always easy. There were some instances where 
families were overwhelmed, and thinking about signing various consent forms and learning 
about a research study was too much to handle at a vulnerable time. I never, however, 
experienced denial of participation or difficult communication with families. I believe a large 
part of this has to do with the close-knit community of PID families, and The Wiskott-Aldrich 
Foundation contributes to this. Because PID is rare, families are much more willing to participate 
in research to really uncover treatment options and unknowns behind the diseases. PIDTC is the 
largest multi-center consortium dedicated to PID, with one protocol for WAS. These patients and 
families seemed excited about the study because of the physicians behind the work and the 
patient advocacy groups they were a part of. It really felt like a family and team that helped each 
other out. I walked away from this experience believing that the heart is not the center of the 
body as most believe, but rather, it’s the immune system.  The University of San Francisco’s 
WISKOTT ALDRICH SYNDROME QUALITY OF LIFE 
19 
 
healthcare graduate program aims to prepare students to be leaders and problem solvers in an 
evolving healthcare realm, and I feel that my courses supplemented my fieldwork experience to 
deliver just that.  I hope to extend my research and work to get vulnerable patients the emotional 
care they need. 
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Final Learning Objectives 
 
Goal 1: To estimate survival for patients with Wiskott-Aldrich Syndrome (WAS) at 6 months and 1, 2, 3, 5, 10, and 15 years post-HCT (hematopoietic 
stem cell transplantation), and to study risk factors for overall survival in this patient population 
Objectives (S) Activities Start/End Date Who is Responsible Tracking Measures 
Evaluate patient, donor, and 
transplant factors 
Use EMR for UCSF patients 
to enter longitudinal data 
into data management site 
(DMCC) 
September 1 – December 31, 
2016 
Tara Bani-Hashemi Number of completed case 
report forms (CRFs) in 
DMCC database for UCSF 
WAS patients entered  
Determine proportion of 
subjects having successful 
immunologic and 
hematologic reconstitution, 
including T cell 
function, B cell function, and 
platelet numbers at 100 
days, 6 months and 1, 2, 3-5, 
6-10, 11-15, and > 15 
years after HCT for WAS 
Use EMR for UCSF patients 
to enter longitudinal data 
into data management site 
(DMCC) 
September 1 – December 31, 
2016 
Tara Bani-Hashemi and 
PIDTC statistician  
Number of completed case 
report forms (CRFs) in 
DMCC database for UCSF 
WAS patients entered 
Evaluate engraftment and 
quality of immune 
reconstitution as 
contributors to clinical 
outcome, including 
occurrence 
of post-transplant infections, 
bleeding episodes, and/or 
new malignancies, GVHD, 
autoimmunity, growth 
and development, and 
quality of life. 
Use EMR for UCSF patients 
to enter longitudinal data 
into data management site 
(DMCC) 
September 1 – December 31, 
2016 
Tara Bani-Hashemi and 
PIDTC statistician 
Number of completed case 
report forms (CRFs) in 
DMCC database for UCSF 
WAS patients entered 
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Evaluate current survivors of 
HCT for WAS as to 
the effects of patient, donor 
and transplant-related 
factors on the degree of 
immune reconstitution of T, 
B, and NK cells, and 
normalization of peripheral 
blood platelet counts. 
Consent WAS patients to 
Cross-Sectional portion of 
study in the UCSF BMT unit 
clinic 
September 1 – December 31, 
2016 
Tara Bani-Hashemi Number of UCSF WAS 
patients who came into 
BMT clinic for the follow-
up/cross-sectional visit. 
 
Number of consents 
collected 
Evaluate cross-sectional 
visits showing current 
survivors of HCT for WAS as 
to the effects of patient, 
donor, and transplant-
related factors on current 
health 
Administer Quality of Life 
surveys, collect Karnofsky 
or Lansky functional scores 
from physician notes 
September 1 – December 31, 
2016 
Tara Bani-Hashemi Number of UCSF WAS 
patients who came into 
BMT clinic for the follow-
up/cross-sectional visit. 
 
Number of surveys and data 
points collected 
Maintain IRB approvals and 
modifications for UCSF’s 
6904 WAS study 
Submit modification forms, 
change in study personnel, 
protocol changes, and 
annual renewals to UCSF 
IRB 
September 1 – December 31, 
2016 
Tara Bani-Hashemi Compliance with IRB and 
maintenance of renewal 
terms 
 
Goal 2: To improve the quality of life for patients and families of patients diagnosed with Wiskott-Aldrich syndrome through raising 
awareness of the effects of WAS and encouragement of questioning QoL through surveying.  
Objectives (S) Activities Start/End Date Who is Responsible  
Research past QoL studies 
and effectiveness 
Tara to conduct research 
on previous studies 
involving importance of 
QoL surveying and 
outcomes 
September 1 – October 1, 
2016 
Tara Bani-Hashemi Good understanding of 
QoL studies and their 
implications through past 
studies 
Familiarize self with Research PedsQL™ and 
differences to QoL 
September 1 – October 1, Tara Bani-Hashemi Good understanding of 
PedsQL™ format and 
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PedsQL™  surveys administered to 
adult patients  
2016 differences to adult quality 
of life surveys 
Understand scoring of QoL 
surveys 
Research QoL scoring 
options and research 
survey study outcomes 
from previous studies 
September 1 – October 1, 
2016 
Tara Bani-Hashemi Good understanding of 
scoring of quality of life 
surveys and how overall 
scores generated 
Maintain IRB consents and 
QoL surveys through UCSF 
IRB 
Submit consent forms 
and QoL surveys as need 
be 
September 1 – December 
31, 2016 
Tara Bani-Hashemi Compliance with IRB and 
maintenance of renewal 
terms 
Create QoL surveys in 
various languages 
Draft, finalize, and submit 
QoL surveys in various 
languages 
September 1 – December 
31, 2016 
Tara Bani-Hashemi Submission of various 
language QoLs to IRB and 
wider distribution at UCSF 
due to larger reach 
Administer QoL surveys to 
UCSF WAS patients at 
cross-sectional visits 
Tara to attend cross-
sectional visits for WAS 
patients in BMT clinic to 
consent and administer 
surveys for PIDTC study 
September 1 – December 
31, 2016 
Tara Bani-Hashemi Number of UCSF WAS 
patients who came into 
BMT clinic for the follow-
up/cross-sectional visit. 
 
Number of surveys and 
data points collected 
Data entry of QoL results Enter collected cross-
sectional data into DMCC 
database for analysis 
September 1 – December 
31, 2016 
Tara Bani-Hashemi & 
PIDTC statistician  
Number of completed case 
report forms (CRFs) in 
DMCC database for UCSF 
WAS patients entered 
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Master of Public Health Program FIELDWORK TIME LOG 
 
 
Student Informat ion  
 
Student’s Name: Tara Bani-Hashemi 
 
Campus ID # 20377211 
 
Student’s Phone: (925) 262-7817 
 
Student’s Email: tbanihashemi@usfca.dons.edu 
Preceptor  Information 
 
Preceptor’s Name: Sumathi Iyengar M.D. 
 
Preceptor’s Title: Executive Director 
 
Preceptor’s Phone: 919-641-7134 
 
Preceptor’s Email: sumathi.iyengar@wiskott.org 
 
Organization: Wiskott-Aldrich Foundation 
 
Student’s Start Date: September 1st, 2016 
 
Student’s End Date: 20hrs/wk through December 31st, 2016 
 
 
Time Log for (Check One): 
 
_________________ Summer 2016 __________X__________Fall  2016 
 
 
 
_________________ Summer 2017 _____________________Fall  2017 
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Master of Public Health Program Student Time Sheet 
 
Week Total # of Hours for Week Preceptor Initials 
Sep 1-8, 2016 20 SI 
Sep 8-15, 2016 20 SI 
Sep 15-22, 2016 20 SI 
Sep 22-29, 2016 20 SI 
Sep 29-Oct 6, 2016 20 SI 
Oct 6-13, 2016 20 SI 
Oct 13-20, 2016 20 SI 
Oct 20-27, 2016 20 SI 
Oct 27-Nov 3, 2016 20 SI 
Nov 3-10, 2016 20 SI 
Nov 10-17, 2016 20 SI 
Nov 17-24, 2016 0 SI 
Nov 24-Dec 1, 2016 20 SI 
Dec 1-8, 2016 20 SI 
Dec 8-15, 2016 20 SI 
Dec 15-22, 2016 20 SI 
Dec 22-29, 2016 0 SI 
Total 300 
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Student Evaluation of Field Experience 
 
 
Student Information  
Student’s Name: Tara Bani-Hashemi Campus ID # 20377211 
Student’s Phone: (925) 262-7817 Student’s Email: tbanihashemi@usfca.dons.edu 
Preceptor Information  
Preceptor’s Name: Sumathi Iyengar M.D. Preceptor’s Title: Executive Director 
Preceptor’s Phone: 919-641-7134 Preceptor’s Email: sumathi.iyengar@wiskott.org 
Organization: Wiskott-Aldrich Foundation 
Student’s Start Date: September 1st, 2016 
Student’s End Date: 20hrs/wk through December 
31st, 2016 
 
Please use the following key to respond to the statements listed below. 
SA = Strongly Agree  A = Agree  D = Disagree  SD = Strongly Disagree   N/A = Not Applicable 
My Field Experience…   
Contributed to the development of my specific career interests SA A D SD N/A 
 
 
Provided me with the opportunity to carry out my field learning objective activities 
 
 
SA 
 
 
A 
 
 
D 
 
 
SD 
 
 
N/A 
Provided the opportunity to use skills obtained in MPH classes SA A D SD N/A 
Required skills I did not have 
Please list: Patient-
interaction in a professional 
healthcare setting  
 
 
SA 
 
 
A 
 
 
D 
 
 
SD 
 
 
N/A 
Required skills I have but did not gain in the MPH program 
Please list: Acquired professional research skills not 
gained during program  
 
 
SA 
 
 
A 
 
 
D 
 
 
SD 
 
 
N/A 
Added new information and/or skills to my graduate education 
Please list: Work experience, time-management, independent 
learning, research analysis  
 
 
SA 
 
 
A 
 
 
D 
 
 
SD 
 
 
N/A 
Challenged me to work at my highest level SA A D SD N/A 
Served as a valuable learning experience in public health practice SA A D SD N/A 
I would recommend this agency to others for future field experiences. Yes   NO  
My preceptor…  
Was valuable in enabling me to achieve my field learning objectives SA A D SD N/A 
Was accessible to me SA A D SD N/A 
 
Initiated communication relevant to my special assignment that he/she considered of 
interest to me 
 
 
SA 
 
 
A 
 
 
D 
 
 
SD 
 
 
N/A 
 
 
Initiated communication with me relevant to general functions of the agency 
 
 
SA 
 
 
A 
 
 
D 
 
 
SD 
 
 
N/A 
 Tara Bani-Hashemi 
26 
 
 
 
2. Would you recommend this preceptor for future field experiences? Please explain. 
 
 X Yes  No  Unsure 
 
Dr. Iyengar was eager to help at all times, and was able to give me access to many valuable 
resources and publications that I would not come across on my own. She is a very valued 
member in the PID community and I feel very fortunate to have worked with her on a 
professional level.  
 
3. Please provide additional comments explaining any of your responses. 
 
I would strongly recommend any future students to work with and help the Wiskott-Aldrich 
Foundation. I believe as public health professionals, it is our duty to better understand 
populations in need and do whatever we can to support the patients and their families financially, 
emotionally, and using any resources we may have.  
 
 
 
4. Summary Report: All students are required to prepare a written summary of the field 
work to be submitted with this evaluation form. 
 
 
 
 
 
 
 
Student Signature    Date  
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Master of Public Health Program 
Preceptor Evaluation of Student in Fieldwork Experience 
The purpose of this form is to provide the preceptor with an opportunity to evaluate the student’s 
performance in the Field Experience. The preceptor and student should review and discuss this evaluation 
together before it is submitted.  
 
Student’s Name: Tara Bani-Hashemi 
 
Preceptor’s Name: Sumathi Iyengar M.D. 
Preceptor’s Title: Executive Director 
Preceptor’s Email: sumathi.iyengar@wiskott.org 
 
Please rate the student’s performance during the field experience based on the following criteria:  
N/A – Not applicable 
1 = Unacceptable at this point in training 
2 = Somewhat below expectations 
3 = Met expectations 
4 = Consistently exceeded expectations 
COURSE REQUIREMENTS:  
Achieved Field Experience Learning Objectives 
(see Field Learning Agreement)           
Completed defined project in 
Public Health Practice           
Worked effectively with 
Preceptor           
Worked effectively within 
Organization           
Integrated public health theory 
into public health practice           
Demonstrated an appropriate level 
of public health skills and 
knowledge in field experience           
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PUBLIC HEALTH SKILLS AND 
KNOWLEDGE:            
Able to apply the core function of 
assessment in the analysis of public health 
problems. (Assessment)           
Demonstrated an understanding of the 
structure, process, and outcomes of health 
services including costs, financing, 
organization, outcomes, and accessibility. 
(Systems)           
Able to plan for the design, development, 
implementation, and evaluation of strategies 
to improve individual and community health. 
(Program Planning)           
Able to use the basic concepts and skills 
involved in culturally appropriate community 
engagement and empowerment with diverse 
populations. (Cultural Competency)           
Able to prepare a program budget with 
justification. (Financial Planning/Budgets)           
Demonstrated an ability to use collaborative 
methods to achieve community and 
organizational goals. (Leadership)           
WORK HABITS: 
Reliable           
Took initiative in work           
Efficient           
INTERPERSONAL SKILLS: 
Professional demeanor           
Interactions with co-workers           
Interactions with community partners           
 
2. Did the student bring the appropriate knowledge and skills needed to complete the projects 
(s) in your organization? If no, what additional knowledge and skills were needed?  
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3. What was the student’s work helpful or useful to you and your agency/organization? Please 
explain.  
 
 
 
4. Please provide additional comments regarding the student’s performance.  
 
 
 
Final Grade Assigned for Field Experience  (Check One)  
A= Outstanding    
AB= Very Good    
B= Good    
BC= Satisfactory, but below expectations    
C=Marginal Pass    
F=No Credit    
 
 
Preceptor’s Signature:____________________________Date: ____________ 
 
 
 
                    
Student’s Signature:______________________________Date:____________ 
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MPH Program Competency Inventory 
USF MPH Competencies Notes 
1.   Assess, monitor, and review the health status of populations and 
their related determinants of health and illness. 
 
2.   Demonstrate the ability to utilize the proper statistical and 
epidemiologic tools to assess community needs and program 
outcomes. 
 
3.   Identify and prioritize the key dimensions of a public health 
problem by critically assessing public health literature utilizing both 
quantitative and qualitative sources. 
 
4.  Specify approaches for assessing, preventing, and controlling 
environmental hazards that pose risks to human health and safety. 
 
5.   Apply theoretical constructs of social change, health behavior and 
social justice in planning community interventions. 
 
6.  Articulate the relationship between health care delivery and 
financing, public health systems, and public policy. 
 
7.  Apply evidence-based principles to the process of program 
planning, development, budgeting, management, and evaluation in 
public health organizations and initiatives. 
 
8.  Demonstrate leadership abilities as collaborators and coordinators of 
evidence based public health projects. 
 
9.   Identify and apply ethical, moral, and legal principles in all aspects 
of public health practice. 
 
10. Develop public health programs and strategies responsive to the 
diverse cultural values and traditions of the communities being 
served. 
 
11. Effectively communicate public health messages to a variety of 
audiences from professionals to the general public. 
 
12. Advance the mission and core values of the University of San 
Francisco. 
 
 
